Comparison of exposure response relationship of atrasentan between N orth A merican and A sian populations

Authors:

Abstract
Aims: The selective endothelin ( ET ) A receptor antagonist atrasentan has been shown to lower albuminuria in N orth A merican and A sian patients with type 2 diabetes and nephropathy. As drug responses to many drugs may differ between N orth A merican and A sian populations, we assessed the influence of geographical region on the albuminuria and fluid retention response to atrasentan. Materials and methods: Two 12‐week double‐blind randomised controlled trials were performed with atrasentan 0.75 or 1.25 mg/d vs placebo in patients with type 2 diabetes and nephropathy. The efficacy endpoint was the percentage change in albuminuria. Bodyweight change, a proxy of fluid retention, was used as a safety endpoint. Pharmacodynamics were determined in A sians ( N = 77) and N orth A mericans ( N = 134). Atrasentan plasma concentration was measured in 161 atrasentan‐treated patients. Results: Mean albuminuria reduction in Asian, compared to N orth A merican, patients was, respectively, −34.4% vs −26.3% for 0.75 mg/d ( P = .44) and −48.0% vs −28.9% for 1.25 mg/d ( P = .035). Bodyweight gain did not differ between N orth A merican and A sian populations. Atrasentan plasma concentrations were higher in A sians compared to N orth A mericans and correlated with albuminuria response (7.2% albuminuria reduction per doubling atrasentan concentration; P = .024). Body surface area (β = −1.09 per m 2 ; P < .001) and bilirubin, as a marker of hepatic organic anion transporter activity, (β = 0.69 per mg/ dL increment; P = .010) were independent determinants of atrasentan plasma concentration; correction by body surface area and bilirubin left no significant difference in plasma concentration between A sian and N orth A merican populations. Conclusion: The higher exposure and albuminuria reduction of atrasentan in A sian patients is not associated with more fluid retention, suggesting that A sian patients are less sensitive to atrasentan‐induced sodium retention.
Funding Information
  • AbbVie

This publication has 20 references indexed in Scilit: